Viropil
Developed for human immunodeficiency virus infection indicated to support viral load suppression.
Strengths: 50/300/300mg
Where to Check Availability
Medicine details
- Conditions
- Therapeutic class
Antiretroviral
- Pharmacological class
Integrase Inhibitor; NRTI
- Contraindications
hypersensitivity to components; concurrent dofetilide use
- Precautions and warnings
monitor for immune reconstitution syndrome; monitor renal function
- Minor side effects
insomnia; nausea; fatigue; headache
- Moderate side effects
dizziness; abnormal dreams; flatulence
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Prescription status
POM
- Onset Time
1–2 weeks
- Duration
Indefinite
- Storage instructions
Store in original container below 30°C.
- Drug interactions
metformin; antacids; calcium supplements
- Age restrictions
Adults and adolescents based on weight.
- Pregnancy and breastfeeding
Pregnancy: Use with medical supervision. Breastfeeding: Not recommended.
Serious side effects
lactic acidosis — requires immediate medical attention; hepatotoxicity — requires immediate medical attention
Patient summary
Developed for human immunodeficiency virus infection indicated to support viral load suppression.
Mechanism of action
A multi-drug combination that inhibits the HIV integrase enzyme and reverse transcriptase, preventing the virus from replicating or integrating into host cell DNA.
Viropil
Developed for human immunodeficiency virus infection indicated to support viral load suppression.
Editorial Notes
- Active ingredient(s): Dolutegravir, Lamivudine, Tenofovir Disoproxil
- Listed indication(s): HIV Infection
Available option
- 30 tablets - 50/300/300 mg1079-50-300-300-mg-17927